<DOC>
	<DOCNO>NCT00676052</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety GSK233705B compare placebo subject COPD .</brief_summary>
	<brief_title>Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>A sign date write informed consent prior study participation . Male female adult . A female eligible enter participate study : nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female postmenopausal ; childbearing potential , negative pregnancy test Visit 1/Visit 1A , agree one protocolspecified acceptable contraceptive method use consistently correctly ( i.e . accord approved product label instruction physician duration study Screening followup contact ) 40 80 year age Visit 1 An establish clinical history COPD Current previous cigarette smoker history cigarette smoke ≥ 10 packyears 1 . A postalbuterol/salbutamol FEV1/FVC ratio ≤0.70 postalbuterol/salbutamol FEV1 ≥35 ≤70 % predict normal value Subjects meet follow criterion must enrol study : Women pregnant lactating . A current diagnosis asthma . Known respiratory disorder COPD include limited α1 antitrypsin deficiency underlie cause COPD , active tuberculosis , lung cancer , bronchiectasis , sarcoidosis , lung fibrosis , pulmonary hypertension , interstitial lung disease . Any previous lung resection surgery ( e.g. , lung volume reduction surgery lobectomy ) Clinically significant Chest Xray compute tomography ( CT ) scan abnormality within 6 month prior Visit 1 believe due COPD . Use oral corticosteroid antibiotic COPD within 6 week prior Visit 1 . Hospitalization COPD pneumonia within 3 month prior Visit 1 . Use antibiotic low respiratory tract infection within 30 day prior Visit 1 . Clinically significant uncontrolled cardiovascular , neurological , psychiatric , renal , gastrointestinal , immunological , endocrine ( include uncontrolled diabetes thyroid disease ) hematological abnormality . An abnormal clinically significant 12lead electrocardiogram ( ECG ) result active medical problem . Positive Hepatitis B Hepatitis C Visit 1 . A current malignancy previous history cancer remission &lt; 5 year prior Visit 1 A history allergy hypersensitivity ipratropium , tiotropium , atropine derivative , lactose/milk protein magnesium stearate . Medical diagnosis narrowangle glaucoma , prostatic hypertrophy bladder neck obstruction opinion study investigator would prevent use inhaled anticholingeric . Medically unable withhold albuterol/salbutamol 6 hour prior spirometry test study visit withhold ipratropium ( applicable ) 6hour period prior first 3 study visit ( ipratropium use Visit 3 ) . Additional Medications : Unable stop use certain medication bronchodilator corticosteroid protocolspecified time prior Visit 1 ( Investigator discuss specific medication ) Use inhaled corticosteroid dose great 1000 mcg/day fluticasone propionate equivalent within 30 day prior Visit 1 . Use longterm oxygen therapy ( LTOT ) supplemental oxygen require great 12 hour day . Oxygen use need exclusionary . Clinically significant sleep apnea require continuous positive airway pressure ( CPAP ) Use regular nebulized therapy Use nocturnal positive pressure noninvasive positive pressure ventilation ( NIPPV ) Participation acute phase pulmonary rehabilitation program within 4 week prior Visit 1 . An investigator , subinvestigator , study coordinator , employee participate investigator study site , immediate family member involve study History psychiatric disease , intellectual deficiency , poor motivation , substance abuse two year prior Visit 1 ( include drug alcohol ) , condition , limit validity inform consent participate study . Use GSK233705B previous study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Multicenter</keyword>
	<keyword>GSK233705B</keyword>
	<keyword>double-blind</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
	<keyword>randomize</keyword>
</DOC>